Results 251 to 260 of about 108,133 (341)

Deciphering pro‐arrhythmogenic mechanisms of EPAC in human atrial cardiomyocytes

The Journal of Physiology, EarlyView.
Abstract figure legend This study aimed to investigate the effect of exchange proteins directly activated by cAMP (EPAC) on the regulation of human atrial cardiomyocyte electrophysiology and their potential involvement in the onset of atrial fibrillation (AF).
Arthur Boileve, Margaux Aize, Maximin Détrait, Laura Brard, Adrien Leboyer, Pierre‐Antoine Dupont, Alexandre Lebrun, Vladimir Saplacan, Christophe Simard, Fabien Brette, Frank Lezoualc'h, Laurent Sallé   +11 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Zaffar H, Imran MA, Hussain S, Rushd F.
europepmc   +1 more source

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Jaradat JH, Al-Ahmad RI, Al Jaghbeer M, Abdelaziz AA, Abu Afifeh NM, Abu Afifeh G, Rao A, Alzoubi A, Nashwan AJ.   +8 more
europepmc   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. [PDF]

Diabetes Care
Park CM, Thanapluetiwong S, Chen X, Oh G, Ko D, Kim DH.   +5 more
europepmc   +1 more source

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
This systematic literature review and meta‐analysis compared sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) against other metformin‐containing oral dual‐therapies (ODTs) in type 2 diabetes mellitus. SGLT‐2i plus metformin exhibited overall comparable efficacy and safety, with a lower risk of hypoglycaemia and greater weight reduction than other ...
Yuhang Ma, Yi Lin, Xiaoying Ding, Yongde Peng   +3 more
wiley   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. [PDF]

EClinicalMedicine
Eshraghi R, Ghadimi DJ, Montazerinamin S, Bahrami A, Kachela Y, Rezasoltani M, Namazi MJ, Subhani M, Ebrahimi P, Hosseini K.   +9 more
europepmc   +1 more source

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, Volume 183, Issue 5, Page 1030-1047, March 2026.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source

Characteristics and outcomes of cubital tunnel decompression in diabetic patients receiving glucagon-like peptide-1 receptor agonists. [PDF]

Clin Shoulder Elb
Shabbir R, Shamith S, Parente PEL, Nicholson L, Ali A.   +4 more
europepmc   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source